Details for Patent: 8,207,125
✉ Email this page to a colleague
Which drugs does patent 8,207,125 protect, and when does it expire?
Patent 8,207,125 protects KYPROLIS and is included in one NDA.
This patent has eighty-nine patent family members in twenty-seven countries.
Summary for Patent: 8,207,125
| Title: | Compounds for enzyme inhibition |
| Abstract: | Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. |
| Inventor(s): | Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA) |
| Assignee: | Onyx Therapeutics, Inc. (South San Francisco, CA) |
| Application Number: | 13/334,288 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,207,125 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 8,207,125
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Onyx Pharms Amgen | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,207,125
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1781688 | ⤷ Sign Up | PA2016010 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1781688 | ⤷ Sign Up | 93015 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1781688 | ⤷ Sign Up | CA 2016 00014 | Denmark | ⤷ Sign Up |
| European Patent Office | 1781688 | ⤷ Sign Up | 300805 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1781688 | ⤷ Sign Up | 16C0017 | France | ⤷ Sign Up |
| European Patent Office | 1781688 | ⤷ Sign Up | C20160008 00189 | Estonia | ⤷ Sign Up |
| European Patent Office | 1781688 | ⤷ Sign Up | 1690013-6 | Sweden | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
